Natco Pharma’s consolidated net profit rose 425% for the third quarter ended December 31 while its revenue increased by 134% on sales of the generic Tamiflu drug it introduced in the U.S. last year. The net profit increased to ₹194.76 crore as against ₹37.04 crore in the corresponding period of previous fiscal. Total consolidated revenue was ₹685.13 crore (₹293.45 crore). The revenue and profit growth was driven predominantly by the sales of the Oseltamivir (generic Tamiflu) product in the U.S. market and includes profit-sharing from its marketing partner, according to the company. In December, the company had unveiled the generic Tamiflu in the U.S. Natco also declared a second interim dividend of ₹6 on each equity share of ₹2 for 2016-17.
